How to tokenize drug repurposing patents for VC funding

Drug repurposing—finding new therapeutic uses for existing, approved medications—is one of the most efficient pathways in biotechnology. Because the safety profiles of these drugs are already established, startups can skip years of Phase I clinical trials, drastically reducing time-to-market.

However, securing Venture Capital (VC) funding for drug repurposing remains a massive hurdle. Traditional VC firms are wary of the intellectual property (IP) risks. A method-of-use patent is often seen as weaker than a composition-of-matter patent, making investors hesitant to inject the millions required for Phase II and III trials. Startups need a way to instantly monetize their discoveries and provide clear IP security to attract funding.

Digital Patent AI offers a revolutionary mechanism to secure VC funding: tokenizing your drug repurposing patents as Real World Assets (RWAs).

Tokenizing biotech IP to attract venture capital

Instead of relying solely on traditional equity rounds, biotech startups can use Digital Patent AI to tokenize the commercial rights to their repurposed drug patents. Our platform utilizes a paired-token smart contract system:

1. Non-Exclusive Tokens: You can issue digital licenses allowing research institutions or smaller pharma companies to utilize your data for specific, non-competing applications, generating immediate cash flow.
2. Exclusive Token: A single token representing the absolute, exclusive buyout of the repurposing patent and all associated clinical data.

For a VC firm, this tokenized structure is highly attractive. It provides them with a tangible, liquid asset rather than just illiquid startup equity.

The Exclusive Token as the ultimate exit strategy

The primary goal of VC funding in biotech is a successful exit, usually through acquisition by a major pharmaceutical company (Big Pharma). Our platform streamlines this exit via the Exclusive Token.

If a Big Pharma company wants to acquire your repurposed drug, they don’t need to endure months of complex corporate M&A (Mergers and Acquisitions) negotiations. They simply purchase the Exclusive Token on our marketplace.

The moment the Exclusive Token is purchased, the smart contract algorithmically blocks the issuance of any new non-exclusive tokens. The acquiring pharma company instantly secures total control over the asset, while your startup and your VC backers receive an immediate, massive payout.

A streamlined platform with zero royalties

Digital Patent AI operates with a flat 2.5% platform commission solely on the primary sale of a token. We never demand ongoing royalties or milestone payments that drain your future profits.

Furthermore, our proprietary AI matching engine actively connects your tokenized patents with VC firms and pharmaceutical companies looking for specific therapeutic advancements. This automated tech scouting ensures your innovation gets in front of the right investors instantly.

Secure your funding and accelerate your clinical trials. Tokenize your drug repurposing patents today with Digital Patent AI.